Titan Pharmaceuticals (NSDQ:TTNP) this month revealed a collaboration with the Walter Reed Army Institute of Research to evaluate the use of its ProNeura drug-delivery technology for the long-term prevention of malaria.
The company is already working to develop its implant for an array of applications. Titan president & CEO Sunil Bhonsle told Drug Delivery Business News that this partnership was crucial to extend its reach into malaria.
“They have the expertise that we don’t have internally so this is, for us, very important,” he said.
Get the full story at our sister site, Drug Delivery Business News.